BioAgilytix Grows Its Portfolio of Meso Scale Discovery Electrochemiluminescence (MSD-ECL) Platforms to Over 10 Operating in its USA and European Labs

BioAgilytix Remains the Premier Bioanalytical CRO Providing PK, ADA, NAb and Biomarker Analysis Utilizing MSD-ECL to Support Global Large Molecule Studies

MAY 8, 2017—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, is expanding its advanced laboratories with the purchase of additional Meso Scale Discovery Electrochemiluminescence (MSD-ECL) platforms, bringing its inventory to more than 10 of these instruments distributed across its USA and European locations. This purchase continues the company’s long partnership with proprietary technology manufacturer Meso Scale Discovery (MSD), and its history leveraging the innovative MSD-ECL platform to support robust biologics analysis. BioAgilytix was one of the earliest CROs to realize the power of using MSD-ECL technology to provide optimal results for pharmacokinetics (PK), antidrug antibody (ADA), and neutralizing antibody (NAb) analysis, enabled by the platform’s high sensitivity, low background, assay flexibility, and wide dynamic range. A decade later, BioAgilytix remains the leading bioanalytical CRO with the deep MSD-ECL expertise needed to ensure delivery of reliable, high quality data for a diverse variety of biological assay needs.

msd-ecl platform

“We have been highly successful in leveraging our MSD-ECL platforms to achieve clinical quality data in a variety of sample types, and like that it offers great flexibility with stable, non-radioactive, and easily conjugated labels,” said Dr. Afshin Safavi, Global Chief Scientific Officer of BioAgilytix. “Because of these factors, it makes a strong alternative to conventional colorimetric methods like standard ELISA, particularly for complex matrices and when higher sensitivity and multiplexing are critical. We are committed to delivering the highest quality assays to our customers, and our continued investment in MSD-ECL – both in the purchase of additional platforms and in training our scientists to optimally use these instruments – is another example of how we are globally equipped to meet customers’ complex large molecule challenges.”

“Partnering with industry-leading CROs such as BioAgilytix underscores our shared commitment to helping bioanalytical researchers in all labs access the full power of MSD’s MULTI-ARRAY® technology to advance their studies,” said Dr. James Wilbur, General Manager of MSD.

###

About BioAgilytix

BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, spirit-of-GLP, GLP, and GCP, as well as product release testing under GMP.

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to 23 of the top 25 global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.

Media Contact:
Carla Nieser
Vovéo Marketing Group
610.240.0400, x 118
c.nieser@voveo.com

Share This